13 patents currently held
72 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
20 more records may belong here and await a decision; they are not counted.
The next term ends in Nov 2027. from the record
Of the 72 now held by other companies, 63 name Sanofi as their current owner, and 9 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
7
Ending by 2030
Nov 2027
Next term end
8
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Dec 2033 · High confidence
Also notable
Ends Oct 2032 · High confidence
Also notable
Ends Aug 2028 · High confidence
Compositions Comprising Anti-CD38 Antibodies and Lenalidomide
US 10,342,869
Cited by 56 later US patents, top 5% of utility patents granted in 2019 in our data. Protection runs to 2033.
Novel ANTI-CD38 Antibodies for the Treatment of Cancer
US 8,153,765
The most cited patent in this portfolio, cited by 63 later US patents, top 10% of utility patents granted in 2012 in our data. Protection runs to 2032.
Humanized ANTI-CXCR5 Antibodies, Derivatives Thereof and Their Use
US 9,228,019
The largest patent family in this portfolio, 10 related applications, renewed at every maintenance window due so far. Protection runs to 2028. A terminal disclaimer caps this term to an earlier patent's.
Formerly held, still cited
Notable
Ends May 2029 · High confidence
Cited by 33 later US patents, top 25% of utility patents granted in 2013 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2029.
now held by Sanofi
Also notable
Ends May 2031 · High confidence
Cited by 24 later US patents, top 25% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2031.
now held by Sanofi
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 9, 2027The maintenance fee for Compositions Comprising Anti-CD38 Antibodies and Lenalidomide (US 10,342,869) comes due Jan 9, 2027. Unpaid by Jul 9, 2027, it lapses early.
- 1 fee due May 3, 2027The maintenance fee for Humanized Anti-CXCR5 Antibodies, Derivatives Thereof And Their Use (US 9,175,087) comes due May 3, 2027. Unpaid by Nov 3, 2027, it lapses early.
- 2 fees due Jul 5 to 26, 2027 · next Jul 5
- 1 fee due Sep 26, 2027The maintenance fee for Methods of Treating Multiple Myeloma (US 11,939,390) comes due Sep 26, 2027. Unpaid by Mar 27, 2028, it lapses early.
Recent changes
- 2 of the patents on this record were granted since Aug 17, 2026
- 3 terms have ended since Aug 17, 2026
What they patent
The 5 largest of its 8 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Humanized ANTI-CXCR5 Antibodies, Derivatives Thereof and Their Use | 5 in force | to Aug 2028 |
| Formulations of ANTI-CD38 Antibodies for Subcutaneous Administration | 2 in force | to Aug 2041 |
| Methods of Treating Multiple Myeloma | 1 in force | to Nov 2040 |
| Compositions Comprising ANTI-CD38 Antibodies and Carfilzomib | 1 in force | to Sep 2034 |
| Compositions Comprising Anti-CD38 Antibodies and Lenalidomide | 1 in force | to Dec 2033 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US D693,457 | Inhaler held by Sanofi-Aventis S.A. In force · High confidence | In force | High confidence | |
| US 8,980,262 | Humanized ANTI-CXCR5 Antibodies, Derivatives Thereof and Their Use held by Sanofi In force · High confidence | In force | High confidence | |
| US 9,175,087 | Humanized Anti-CXCR5 Antibodies, Derivatives Thereof And Their Use held by Sanofi In force · High confidence | In force | High confidence | |
| US 9,228,019 | Humanized ANTI-CXCR5 Antibodies, Derivatives Thereof and Their Use held by Sanofi In force · High confidence | In force | High confidence | |
| US 9,243,067 | Humanized Anti-CXCR5 Antibodies, Derivatives Thereof And Their Use held by Sanofi In force · High confidence | In force | High confidence | |
| US 9,815,902 | Humanized Anti-CXCR5 Antibodies, Derivatives Thereof and Their Uses held by Sanofi In force · High confidence | In force | High confidence | |
| US 8,647,309 | Medication Delivery Device In force · High confidence | In force | High confidence | |
| US 8,153,765 | Novel ANTI-CD38 Antibodies for the Treatment of Cancer In force · High confidence | In force | High confidence | |
| US 10,342,869 | Compositions Comprising Anti-CD38 Antibodies and Lenalidomide In force · High confidence | In force | High confidence | |
| US 12,533,411 | Compositions Comprising ANTI-CD38 Antibodies and Carfilzomib In force · High confidence | In force | High confidence |
Also on record, not counted in the 13: 72 patents in force now held by others · 630 patents ended · 15 applications pending · 289 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.